Werewolf Therapeutics, Inc.
HOWL · United States
Share price · HOWL
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HOWL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 21 Aug 2026+102.6%
- 31 Jul 2026-29.4%
- 24 Jul 2026+18.5%
Nothing announced by HOWL that day or the session before.
- 13 Jul 2026-15.3%
Nothing announced by HOWL that day or the session before.
- 30 Jun 2026+16.9%
Nothing announced by HOWL that day or the session before.
- 25 Jun 2026-10.8%
Nothing announced by HOWL that day or the session before.
- 19 May 2026-13.5%
Nothing announced by HOWL that day or the session before.
- 1 Apr 2026+15.1%
Nothing announced by HOWL that day or the session before.
- 26 Mar 2026+10.6%
Nothing announced by HOWL that day or the session before.
- 11 Mar 2026+13.2%
Nothing announced by HOWL that day or the session before.
Share of unusual movement by asset
For each asset, the share of HOWL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | IL-12 receptor (tumor-activated prodrug)Biologic (subtype unspecified) | Non-Hodgkin Lymphoma Advanced Solid Tumors and Non-Hodgkin Lymphoma | |
| Phase 1 | IL-2 receptorProtein / enzyme therapeutic | Non-Small Cell Lung Cancer |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $2.2M | $42M | $9.9M-$9.0M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $6.2M | $22M | —$6.6M operating cash flow | report ↗ |
| 2026-Q1 | — | $8.2M | $47M | $14M-$11M operating cash flow | report ↗ |
| 2025-Q3 | — | $12M | $67M | $16M-$15M operating cash flow | report ↗ |
| 2025-Q2 | — | $13M | $78M | $18M-$15M operating cash flow | report ↗ |
| 2025-Q1 | — | $13M | $93M | $18M-$19M operating cash flow | report ↗ |
| 2024-Q3 | — | $13M | $124M | $17M-$12M operating cash flow | report ↗ |
| 2024-Q2 | — | $15M | $137M | $17M-$14M operating cash flow | report ↗ |
| 2024-Q1 | — | $13M | $160M | $16M-$15M operating cash flow | report ↗ |
| 2023-Q3 | — | $11M | $151M | $8.3M-$7.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $9.6M | $159M | $5.1M-$11M operating cash flow | report ↗ |
| 2023-Q1 | — | $12M | $169M | $12M-$9.9M operating cash flow | report ↗ |
| 2022-Q3 | — | $13M | $142M | $12M-$14M operating cash flow | report ↗ |
| 2022-Q2 | — | $14M | $147M | $15M-$0.3M operating cash flow | report ↗ |
| 2022-Q1 | — | $11M | $145M | $15M-$14M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $45M | $58M | $15M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 106 sales ($4.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-07 | EVNIN LUKE · director | Open-market sale | 107,429 | $0.31 | $33K | Form 4 |
| 2026-07-06 | EVNIN LUKE · director | Open-market sale | 35,770 | $0.32 | $11K | Form 4 |
| 2026-06-29 | EVNIN LUKE · director | Open-market sale | 157,084 | $0.30 | $47K | Form 4 |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 389,216 | $0.35 | $136K | Form 4 |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 27,695 | $0.35 | $10K | Form 4 |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 139,686 | $0.37 | $52K | Form 4 |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 9,939 | $0.37 | $4K | Form 4 |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 120,216 | $0.39 | $47K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 48 reporting institutions held 14.0M shares ($11.6M, 28.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 6,681,307 | $5.6M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 1,217,976 | $1.0M |
| 3 | MPM BIOIMPACT LLC | 1,208,810 | $1.0M |
| 4 | Lynx1 Capital Management LP | 657,786 | $548K |
| 5 | SPHERA FUNDS MANAGEMENT LTD. | 626,810 | $522K |
| 6 | DC Funds, LP | 589,102 | $490K |
| 7 | Squadron Capital Management LLC | 563,535 | $469K |
| 8 | RENAISSANCE TECHNOLOGIES LLC | 516,218 | $430K |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 389,487 | $324K |
| 10 | BANK OF AMERICA CORP /DE/ | 264,583 | $220K |
| 11 | VANGUARD FIDUCIARY TRUST CO | 157,726 | $131K |
| 12 | MILLENNIUM MANAGEMENT LLC | 132,050 | $110K |
| 13 | STATE STREET CORP | 119,168 | $99K |
| 14 | BlackRock, Inc. | 101,608 | $85K |
| 15 | NORTHERN TRUST CORP | 86,851 | $72K |